Piramal Pharma Limited Overview
Pro stress-test →Piramal Pharma operates through three major segments: Contract Development and Manufacturing Organizations (CDMO), Complex Hospital Generics (critical care), and Consumer Healthcare (OTC). The company offers differentiated products and services through 17 global development and manufacturing facilities with distribution in over 100 countries.
Strategic Profile
Pro stress-test →The company is among the Top 3 CDMO players in India and the 13th largest globally. The company reported a consolidated net loss of Rs 99.22 crore in Q2 FY26, with revenue declining 8.83% year-on-year to Rs 2,043.72 crore, indicating near-term operational challenges despite its strong market positioning.
Competitive Landscape
Pro stress-test →Piramal Pharma ranks 3rd in India's CDMO market and 13th globally. The company competes with global CDMO leaders like Catalent, Recro, and domestic players. Its diversified three-segment model (CDMO, hospital generics, consumer healthcare) differentiates it from pure-play CDMO competitors but also exposes it to multiple market cycles.
Industry Context
Piramal Pharma Limited operates in Pharmaceutical Manufacturing & CDMO Services.
Key facts
Founded: 1988 · Headquarters: Mumbai, India · Revenue: ₹2,044 Cr (Q2 FY26) · Market cap: ₹21,708 Cr (~$2.6B)